Ocera Therapeutics, Inc.

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury or failure, and in the areas of unmet medical need. The company was founded in 1998 and is headquartered in Palo Alto, California. As of December 11, 2017, Ocera Therapeutics, Inc. operates as a subsidiary of Mallinckrodt plc. On August 28, 2023, Ocera Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.